Effect of Azithromycin on Pulmonary Function in Patie With <emph type="ital">Pseudomonas aeruginos Randomized Controlled Trial</subtitle>

JAMA - Journal of the American Medical Association

303, 1707

DOI: 10.1001/jama.2010.563

Citation Report

#	Article	IF	Citations
1	Recommended Reading from the University of Chicago Pulmonary and Critical Care Fellows. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1453-1454.	2.5	0
2	Potential of anti-inflammatory treatment for cystic fibrosis lung disease. Journal of Inflammation Research, 2010, 3, 61.	1.6	11
3	TLR5 as an Anti-Inflammatory Target and Modifier Gene in Cystic Fibrosis. Journal of Immunology, 2010, 185, 7731-7738.	0.4	59
4	Azithromycin paradox in the treatment of cystic fibrosis airway disease. Future Microbiology, 2010, 5, 1315-1319.	1.0	3
5	Managing Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1463-1471.	2.5	245
7	Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease. Journal of Crohn's and Colitis, 2011, 5, 222-226.	0.6	37
8	Preventing Exacerbations of COPD â€" Advice from Hippocrates. New England Journal of Medicine, 2011, 365, 753-754.	13.9	12
9	New and investigational treatments in cystic fibrosis. Therapeutic Advances in Respiratory Disease, 2011, 5, 275-282.	1.0	10
10	Azithromycin for Prevention of Exacerbations of COPD. New England Journal of Medicine, 2011, 365, 689-698.	13.9	1,057
11	Novel concepts in evaluating antimicrobial therapy for bacterial lung infections in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2011, 10, 387-400.	0.3	23
12	Treatment of Non-Cystic Fibrosis Bronchiectasis. Archivos De Bronconeumologia, 2011, 47, 599-609.	0.4	12
13	Update on methicillin-resistant Staphylococcus aureus in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2011, 17, 437-441.	1.2	35
14	Lack of efficacy of longâ€term, lowâ€dose azithromycin in chronic rhinosinusitis: a randomized controlled trial. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1457-1468.	2.7	151
16	Recent advances in the treatment of Pseudomonas aeruginosainfections in cystic fibrosis. BMC Medicine, 2011, 9, 32.	2.3	201
17	Clinical Year in Review II: Lung Cancer, Sleep Apnea, Interventional Pulmonary/Pleural Disease, Cystic Fibrosis. Proceedings of the American Thoracic Society, 2011, 8, 398-403.	3.5	4
18	Update in Cystic Fibrosis 2010. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1620-1624.	2.5	17
19	Denufosol Tetrasodium in Patients with Cystic Fibrosis and Normal to Mildly Impaired Lung Function. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 627-634.	2.5	71
20	Lack of Association of Small-Colony-Variant Staphylococcus aureus Strains with Long-Term Use of Azithromycin in Patients with Cystic Fibrosis. Journal of Clinical Microbiology, 2011, 49, 2772-2773.	1.8	10

#	Article	IF	Citations
21	Effectiveness and safety of macrolides in cystic fibrosis patients: a meta-analysis and systematic review. Journal of Antimicrobial Chemotherapy, 2011, 66, 968-978.	1.3	60
22	Immunomodulatory Effects of Macrolide Antibiotics â€“ Part 2: Advantages and Disadvantages of Long-Term, Low-Dose Macrolide Therapy. Respiration, 2011, 81, 75-87.	1.2	69
23	A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutation. New England Journal of Medicine, 2011, 365, 1663-1672.	13.9	1,920
24	Hot off the breath: â€˜I've a cost forâ€™â€”the 64 million dollar question: Table 1. Thorax, 2012, 67, 382-384.	2.7	22
25	The Role of Macrolides in Childhood Non-Cystic Fibrosis-Related Bronchiectasis. Mediators of Inflammation, 2012, 2012, 1-7.	1.4	12
26	Effect of antibiotic treatment on fat absorption in mice with cystic fibrosis. Pediatric Research, 2012, 71, 4-12.	1.1	14
27	Inhaled Hypertonic Saline in Infants and Children Younger Than 6 Years With Cystic Fibrosis. JAMA - Journal of the American Medical Association, 2012, 307, 2269-77.	3.8	175
28	Effect of Azithromycin on Systemic Markers of Inflammation in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa. Chest, 2012, 142, 1259-1266.	0.4	110
29	Long-Term Combination Treatment of Azithromycin with Other Macrolides: A New Era. Internal Medicine, 2012, 51, 1289-1291.	0.3	0
30	Effect of Azithromycin on Pulmonary Function in Patients With Cystic Fibrosis Uninfected With Pseudomonas aeruginosa: A Randomized Controlled Trial. Yearbook of Pediatrics, 2012, 2012, 538-540.	0.2	0
31	Longâ€term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clinical and Experimental Allergy, 2012, 42, 1302-1312.	1.4	70
32	Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet, The, 2012, 380, 660-667.	6.3	500
33	The evolution of exercise capacity and its limiting factors in Cystic Fibrosis. Paediatric Respiratory Reviews, 2012, 13, 195-199.	1.2	42
34	Cystic Fibrosis: What to Expect now in the Early Adult Years. Paediatric Respiratory Reviews, 2012, 13, 206-214.	1.2	46
35	A survey on pulmonary pathogens and their antibiotic susceptibility among cystic fibrosis patients. Brazilian Journal of Infectious Diseases, 2012, 16, 122-128.	0.3	7
36	Progress in cystic fibrosis and the CF Therapeutics Development Network. Thorax, 2012, 67, 882-890.	2.7	60
37	Optimization of antiâ€pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: I. aztreonam and carbapenems. Pediatric Pulmonology, 2012, 47, 1147-1158.	1.0	35
38	Long term effects of denufosol tetrasodium in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 539-549.	0.3	85

#	Article	IF	Citations
39	Treatment of lung infection in patients with cystic fibrosis: Current and future strategies. Journal of Cystic Fibrosis, 2012, 11, 461-479.	0.3	421
40	Macrolide antibiotics for cystic fibrosis. The Cochrane Library, 2012, 11, CD002203.	1.5	161
41	Pulmonary Disease in Cystic Fibrosis. , 2012, , 770-780.		6
42	Efeito anti-inflamatÃ³rio dos macrolÃdeos em doenÃ§as pulmonares da infÃ¢ncia. Jornal Brasileiro De Pneumologia, 2012, 38, 786-796.	0.4	9
43	Openâ€label, followâ€on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa. Pediatric Pulmonology, 2012, 47, 641-648.	1.0	40
44	Clarithromycin therapy for patients with Cystic Fibrosis: A randomized controlled trial. Pediatric Pulmonology, 2012, 47, 551-557.	1.0	23
45	Azithromycin maintenance therapy in patients with cystic fibrosis: A dose advice based on a review of pharmacokinetics, efficacy, and side effects. Pediatric Pulmonology, 2012, 47, 658-665.	1.0	23
46	The Sensitivity of Lung Disease Surrogates in Detecting Chest CT Abnormalities in Children With Cystic Fibrosis. Pediatric Pulmonology, 2012, 47, 567-573.	1.0	23
47	Long-Term Inhaled Dry Powder Mannitol in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 645-652.	2.5	117
48	Cystic fibrosis: a mucosal immunodeficiency syndrome. Nature Medicine, 2012, 18, 509-519.	15.2	417
49	Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases. European Journal of Clinical Pharmacology, 2012, 68, 479-503.	0.8	235
50	Clarithromycin for prevention of bronchiolitis obliterans syndrome in lung allograft recipients. Clinical Transplantation, 2012, 26, 105-110.	0.8	8
51	Bronchiectasis exacerbation study on azithromycin and amoxycillin-clavulanate for respiratory exacerbations in children (BEST-2): study protocol for a randomized controlled trial. Trials, 2013, 14, 53.	0.7	16
53	Antibiotic Prophylaxis in Primary Immune Deficiency Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 573-582.	2.0	70
54	Development of a Population Pharmacokinetic Model To Describe Azithromycin Whole-Blood and Plasma Concentrations over Time in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2013, 57, 3194-3201.	1.4	12
55	The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection. Expert Review of Respiratory Medicine, 2013, 7, 385-396.	1.0	11
56	Long-term multicentre randomised controlled study of high frequency chest wall oscillation versus positive expiratory pressure mask in cystic fibrosis. Thorax, 2013, 68, 746-751.	2.7	81
57	Incidence and clinical significance of elevated liver function tests in cystic fibrosis clinical trials. Contemporary Clinical Trials, 2013, 34, 232-238.	0.8	16

#	Article	IF	Citations
59	Impact of acute antibiotic therapy on the pulmonary exacerbation endpoint in cystic fibrosis clinical trials. Contemporary Clinical Trials, 2013, 36, 99-105.	0.8	8
60	Acute antibiotic use in cystic fibrosis clinical trials: does it affect our assessment of clinical efficacy?. Lancet Respiratory Medicine,the, 2013, 1, 98-99.	5.2	3
61	Pitfalls of Drug Development: Lessons Learned from Trials of Denufosol in Cystic Fibrosis. Journal of Pediatrics, 2013, 162, 676-680.	0.9	40
62	Mitochondrial OXPHOS function is unaffected by chronic azithromycin treatment. Journal of Cystic Fibrosis, 2013, 12, 682-687.	0.3	9
63	Gut bacterial microbiota and obesity. Clinical Microbiology and Infection, 2013, 19, 305-313.	2.8	232
65	Early lung disease in cystic fibrosis. Lancet Respiratory Medicine,the, 2013, 1, 148-157.	5.2	80
66	Cystic Fibrosis Pulmonary Guidelines. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 680-689.	2.5	554
67	Long-term macrolide treatment for chronic respiratory disease. European Respiratory Journal, 2013, 42, 239-251.	3.1	124
68	A retrospective analysis of the impact of azithromycin maintenance therapy on adults attending a UK cystic fibrosis clinic. Journal of Cystic Fibrosis, 2013, 12, 49-53.	0.3	14
69	Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: The early intervention in cystic fibrosis exacerbation (eICE) trial. Contemporary Clinical Trials, 2013, 36, 460-469.	0.8	32
70	Early intervention studies in infants and preschool children with cystic fibrosis: are we ready?. European Respiratory Journal, 2013, 42, 527-538.	3.1	49
71	Macrolides and Bronchiectasis. JAMA - Journal of the American Medical Association, 2013, 309, 1295.	3.8	21
72	Effect of Azithromycin Maintenance Treatment on Infectious Exacerbations Among Patients With Nonâ€“Cystic Fibrosis Bronchiectasis. JAMA - Journal of the American Medical Association, 2013, 309, 1251.	3.8	421
73	Antibiotic resistance in Prevotella species isolated from patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2013, 68, 2369-2374.	1.3	36
74	Treatment of pulmonary exacerbations in cystic fibrosis. European Respiratory Review, 2013, 22, 205-216.	3.0	108
75	Macrolide therapy in cystic fibrosis: new developments in clinical use. Clinical Investigation, 2013, 3, 1179-1186.	0.0	1
76	Treatment of Pseudomonas andStaphylococcusBronchopulmonary Infection in Patients with Cystic Fibrosis. Scientific World Journal, The, 2013, 2013, 1-13.	0.8	6
77	Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatment. Jornal Brasileiro De Pneumologia, 2013, 39, 495-512.	0.4	49

#	Article	IF	Citations
78	Antivirulence activity of azithromycin in Pseudomonas aeruginosa. Frontiers in Microbiology, 2014, 5, 178.	1.5	107
79	Meta-Analysis of the Adverse Effects of Long-Term Azithromycin Use in Patients with Chronic Lung Diseases. Antimicrobial Agents and Chemotherapy, 2014, 58, 511-517.	1.4	68
80	Increased IL-8 production in human bronchial epithelial cells after exposure to azithromycin-pretreatedPseudomonas aeruginosa in vitro. FEMS Microbiology Letters, 2014, 355, 43-50.	0.7	2
81	Anti-Inflammatory Macrolides to Manage Chronic Neutrophilic Inflammation. RSC Drug Discovery Series, 2014, , 206-234.	0.2	3
82	Is there a role for macrolides in severe asthma?. Current Opinion in Pulmonary Medicine, 2014, 20, 95-102.	1.2	42
83	The role of neutrophils in cystic fibrosis. Current Opinion in Hematology, 2014, 21, 16-22.	1.2	76
84	Aspergillus Sensitization or Carriage in Cystic Fibrosis Patients. Pediatric Infectious Disease Journal, 2014, 33, 680-686.	1.1	24
85	Vitamin C Supplementation for Pregnant Smoking Women and Pulmonary Function in Their Newborn Infants. JAMA - Journal of the American Medical Association, 2014, 311, 2074.	3.8	175
86	Obesity and the Use of Antibiotics and Probiotics in Rats. Chemotherapy, 2014, 60, 162-167.	0.8	16
87	Azithromycin: Mechanisms of action and their relevance for clinical applications. , 2014, 143, 225-245.		448
88	Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis. Journal of Cystic Fibrosis, 2014, 13, 164-171.	0.3	31
89	Effectiveness and safety of macrolides in bronchiectasis patients: A meta-analysis and systematic review. Pulmonary Pharmacology and Therapeutics, 2014, 28, 171-178.	1.1	25
90	Pulmonary exacerbations in CF patients with early lung disease. Journal of Cystic Fibrosis, 2014, 13, 74-79.	0.3	24
91	Macrolides Are Associated with a Better Survival Rate in Patients Hospitalized with Community-Acquired But Not Healthcare-Associated Pneumonia. Surgical Infections, 2014, 15, 283-289.	0.7	8
92	Long-term macrolide maintenance therapy in non-CF bronchiectasis: Evidence and questions. Respiratory Medicine, 2014, 108, 1397-1408.	1.3	58
93	Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis. Lancet, The, 2014, 384, 703-713.	6.3	130
94	Prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: Meta-analysis of randomized controlled trials. Pulmonary Pharmacology and Therapeutics, 2014, 29, 80-88.	1.1	29
95	Risk Factors for the Progression of Cystic Fibrosis Lung Disease throughout Childhood. Annals of the American Thoracic Society, 2014, 11, 63-72.	1.5	60

#	Article	IF	Citations
96	Advances in the Diagnosis and Treatment of Cystic Fibrosis. Advances in Pediatrics, 2014, 61, 225-243.	0.5	13
98	Azithromycin analogue <scp>CSY</scp>0073 attenuates lung inflammation induced by <scp>LPS</scp> challenge. British Journal of Pharmacology, 2014, 171, 1783-1794.	2.7	44
99	European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. Journal of Cystic Fibrosis, 2014, 13, S23-S42.	0.3	438
101	Reduced risk of nontuberculous mycobacteria in cystic fibrosis adults receiving long-term azithromycin. Journal of Cystic Fibrosis, 2015, 14, 594-599.	0.3	37
102	Antibiotics for preventing lower respiratory tract infections in high-risk children aged 12 years and under. The Cochrane Library, 2015, 2015, CD011530.	1.5	15
103	Risk of hemoptysis in cystic fibrosis clinical trials: A retrospective cohort study. Journal of Cystic Fibrosis, 2015, 14, 632-638.	0.3	21
104	The Evolution of Cystic Fibrosis Care. Chest, 2015, 148, 533-542.	0.4	43
105	Outcomes and Treatment of Chronic Methicillin-ResistantStaphylococcus aureusDiffers by Staphylococcal Cassette Chromosomemec(SCCmec) Type in Children With Cystic Fibrosis. Journal of the Pediatric Infectious Diseases Society, 2015, 4, 225-231.	0.6	15
106	Pulmonary exacerbations and parentâ€reported outcomes in children <6 years with cystic fibrosis. Pediatric Pulmonology, 2015, 50, 236-243.	1.0	19
107	Azithromycin use in patients with cystic fibrosis. European Journal of Clinical Microbiology and Infectious Diseases, 2015, 34, 1071-1079.	1.3	43
108	Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. Journal of Cystic Fibrosis, 2015, 14, 228-236.	0.3	36
109	Cystic fibrosis. Nature Reviews Disease Primers, 2015, 1, 15010.	18.1	403
110	Precision Medicine: At What Price?. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 658-659.	2.5	36
111	Impact of Sustained Eradication of NewPseudomonas aeruginosaInfection on Long-term Outcomes in Cystic Fibrosis. Clinical Infectious Diseases, 2015, 61, 707-715.	2.9	66
112	Efficacy and adverse effects of drugs used to treat adult cystic fibrosis. Expert Opinion on Drug Safety, 2015, 14, 401-411.	1.0	6
113	Challenges in the development of new therapies for bronchiectasis. Expert Opinion on Pharmacotherapy, 2015, 16, 833-850.	0.9	20
114	Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. Journal of Cystic Fibrosis, 2015, 14, 419-430.	0.3	371
115	Early pulmonary inflammation and lung damage in children with cystic fibrosis. Respirology, 2015, 20, 569-578.	1.3	21

#	Article	IF	Citations
116	Use of macrolides in lung diseases: recent literature controversies. Jornal De Pediatria, 2015, 91, S52-S60.	0.9	14
117	Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Therapeutic Advances in Respiratory Disease, 2015, 9, 313-326.	1.0	60
118	Azithromycin for the Prevention of COPD Exacerbations: The Good, Bad, and Ugly. American Journal of Medicine, 2015, 128, 1362.e1-1362.e6.	0.6	35
120	Nonâ€“anti-infective Effects of Antimicrobials and Their Clinical Applications. Mayo Clinic Proceedings, 2015, 90, 109-127.	1.4	40
121	Azithromycin for the Treatment of Eosinophilic Nasal Polyposis: Clinical and Histologic Analysis. Allergy and Rhinology, 2016, 7, ar.2016.7.0160.	0.7	2
122	Azithromycin Attenuates Pseudomonas-Induced Lung Inflammation by Targeting Bacterial Proteins Secreted in the Cultured Medium. Frontiers in Immunology, 2016, 7, 499.	2.2	10
123	Evidence and Role for Bacterial Mucin Degradation in Cystic Fibrosis Airway Disease. PLoS Pathogens, 2016, 12, e1005846.	2.1	170
124	Impact of Azithromycin on the Quorum Sensing-Controlled Proteome of Pseudomonas aeruginosa. PLoS ONE, 2016, 11, e0147698.	1.1	37
125	Macrolides for Acute Wheezing Episodes in Preschool Children. Pediatric, Allergy, Immunology, and Pulmonology, 2016, 29, 100-103.	0.3	6
126	Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature. Diabetes, Obesity and Metabolism, 2016, 18, 444-453.	2.2	62
127	Study protocol, rationale and recruitment in a European multi-centre randomized controlled trial to determine the efficacy and safety of azithromycin maintenance therapy for 6Âmonths in primary ciliary dyskinesia. BMC Pulmonary Medicine, 2016, 16, 104.	0.8	50
128	New and emerging targeted therapies for cystic fibrosis. BMJ, The, 2016, 352, i859.	3.0	112
130	Clinical management of community acquired pneumonia in the elderly patient. Expert Review of Respiratory Medicine, 2016, 10, 1211-1220.	1.0	25
131	Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis. Expert Review of Respiratory Medicine, 2016, 10, 1221-1228.	1.0	5
132	Long-term effects of azithromycin in patients with cystic fibrosis. Respiratory Medicine, 2016, 117, 1-6.	1.3	42
133	Cystic Fibrosis. Pediatric Clinics of North America, 2016, 63, 617-636.	0.9	38
134	Biomarkers for cystic fibrosis drug development. Journal of Cystic Fibrosis, 2016, 15, 714-723.	0.3	52
135	Cystic fibrosis lung environment and Pseudomonas aeruginosa infection. BMC Pulmonary Medicine, 2016, 16, 174.	0.8	268

#	Article	IF	Citations
136	Treatment of Pulmonary Exacerbations Improves Short But Not Longâ€Term Growth Trajectory in Children With Cystic Fibrosis. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, e54-e57.	0.9	0
137	Physiologic endpoints for clinical studies for cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 416-423.	0.3	69
138	Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation. Expert Review of Precision Medicine and Drug Development, 2016, 1, 235-243.	0.4	34
139	Macrolides for Reducing Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Clinical Pulmonary Medicine, 2016, 23, 16-22.	0.3	0
140	Prevention of antibioticâ€associated metabolic syndrome in mice by intestinal alkaline phosphatase. Diabetes, Obesity and Metabolism, 2016, 18, 519-527.	2.2	32
141	Question 5: What is the role of macrolide antibiotics as anti-inflammatory treatment in Cystic fibrosis?. Paediatric Respiratory Reviews, 2016, 18, 55-57.	1.2	0
142	Improvements in symptomatic treatment strategies for cystic fibrosis: delivering CF care in the 21st century. Expert Opinion on Orphan Drugs, 2016, 4, 5-19.	0.5	2
143	Omega-3 fatty acids prevent early-life antibiotic exposure-induced gut microbiota dysbiosis and later-life obesity. International Journal of Obesity, 2016, 40, 1039-1042.	1.6	53
144	The clinical management of lower respiratory tract infections. Expert Review of Respiratory Medicine, 2016, 10, 441-452.	1.0	2
145	CFTR and Cystic Fibrosis. , 2016, , 519-552.		3
146	Systematic review of antibiotic resistance in acne: an increasing topical and oral threat. Lancet Infectious Diseases, The, 2016, 16, e23-e33.	4.6	180
147	Innate and Adaptive Immunity in Cystic Fibrosis. Clinics in Chest Medicine, 2016, 37, 17-29.	0.8	73
148	Cystic Fibrosis and Its Management Through Established and Emerging Therapies. Annual Review of Genomics and Human Genetics, 2016, 17, 155-175.	2.5	33
150	Microbiota manipulation for weight change. Microbial Pathogenesis, 2017, 106, 146-161.	1.3	63
151	Immunomodulatory indications of azithromycin in respiratory disease: a concise review for the clinician. Postgraduate Medicine, 2017, 129, 493-499.	0.9	69
152	Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: A statistical perspective for the clinical researcher. Journal of Cystic Fibrosis, 2017, 16, 318-326.	0.3	90
153	Anti-Inflammatory Therapies for Cystic Fibrosis. Milestones in Drug Therapy, 2017, , 139-151.	0.1	3
154	The treatment of the pulmonary and extrapulmonary manifestations of cystic fibrosis. Presse Medicale, 2017, 46, e139-e164.	0.8	12

#	Article	IF	Citations
155	Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 358-366.	0.3	49
156	Early Lung Disease in Infants and Preschool Children with Cystic Fibrosis. What Have We Learned and What Should We Do about It?. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1567-1575.	2.5	97
157	MicroRNA-9 downregulates the ANO1 chloride channel and contributes to cystic fibrosis lung pathology. Nature Communications, 2017, 8, 710.	5.8	56
158	Prevalence of hearing and vestibular loss in cystic fibrosis patients exposed to aminoglycosides. Pediatric Pulmonology, 2017, 52, 1157-1162.	1.0	26
159	Mapping targetable inflammation and outcomes with cystic fibrosis biomarkers. Pediatric Pulmonology, 2017, 52, S21-S28.	1.0	10
160	Clinical care of children with primary ciliary dyskinesia. Expert Review of Respiratory Medicine, 2017, 11, 779-790.	1.0	47
161	Long-term management of patients with end-stage lung diseases. Bailliere's Best Practice and Research in Clinical Anaesthesiology, 2017, 31, 167-178.	1.7	6
162	Strategies for the etiological therapy of cystic fibrosis. Cell Death and Differentiation, 2017, 24, 1825-1844.	5.0	45
163	An update on new and emerging therapies for cystic fibrosis. Expert Opinion on Emerging Drugs, 2017, 22, 331-346.	1.0	20
165	The Likelihood of Preventing Respiratory Exacerbations in Children and Adolescents with either Chronic Suppurative Lung Disease or Bronchiectasis. Frontiers in Pediatrics, 2017, 5, 58.	0.9	5
166	Brazilian guidelines for the diagnosis and treatment of cystic fibrosis. Jornal Brasileiro De Pneumologia, 2017, 43, 219-245.	0.4	73
167	Changes in weight and body fat after use of tetracycline and Lactobacillus gasseri in rats. Brazilian Journal of Pharmaceutical Sciences, 2017, 53, .	1.2	9
168	Pseudomonas aeruginosa Extracellular Secreted Molecules Have a Dominant Role in Biofilm Development and Bacterial Virulence in Cystic Fibrosis Lung Infections. , 2017, , .		0
169	ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis, 2018, 17, 153-178.	0.3	521
170	Chronic Azithromycin Use in Cystic Fibrosis and Risk of Treatment-Emergent Respiratory Pathogens. Annals of the American Thoracic Society, 2018, 15, 702-709.	1.5	28
171	Staphylococcus aureus in the airways of cystic fibrosis patients - A retrospective long-term study. International Journal of Medical Microbiology, 2018, 308, 631-639.	1.5	53
172	Effects of an Antioxidant-enriched Multivitamin in Cystic Fibrosis. A Randomized, Controlled, Multicenter Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 639-647.	2.5	34
173	Antibiotics, gut microbiome and obesity. Clinical Endocrinology, 2018, 88, 185-200.	1.2	70

#	Article	IF	Citations
174	Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?. Expert Opinion on Orphan Drugs, 2018, 6, 69-84.	0.5	3
175	Long-term macrolide treatment for the prevention of acute exacerbations in COPD: a systematic review and meta-analysis. International Journal of COPD, 2018, Volume 13, 3813-3829.	0.9	44
176	Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis. Expert Review of Respiratory Medicine, 2018, 12, 569-584.	1.0	8
177	Chronic Antibiotic Use in Cystic Fibrosis: A Fine Balance. Annals of the American Thoracic Society, 2018, 15, 667-668.	1.5	6
178	Reevaluating approaches to cystic fibrosis pulmonary exacerbations. Pediatric Pulmonology, 2018, 53, S51-S63.	1.0	9
179	Metabolomic Analysis by Nuclear Magnetic Resonance Spectroscopy as a New Approach to Understanding Inflammation and Monitoring of Pharmacological Therapy in Children and Young Adults With Cystic Fibrosis. Frontiers in Pharmacology, 2018, 9, 595.	1.6	14
180	Inflammation in cystic fibrosis: An update. Pediatric Pulmonology, 2018, 53, S30-S50.	1.0	187
181	Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1177-1187.	2.5	75
182	Pulmonary Disease in Cystic Fibrosis. , 2019, , 777-787.e4.		4
183	Hyperpolarized Gas Magnetic Resonance Imaging of Pediatric Cystic Fibrosis Lung Disease. Academic Radiology, 2019, 26, 344-354.	1.3	43
184	Cystic Fibrosis: an Update on Disease Pathophysiology, Management, and Novel Modalities of Therapy. Current Treatment Options in Allergy, 2019, 6, 226-237.	0.9	0
185	Appropriate lung management in patients with primary antibody deficiencies. Expert Review of Respiratory Medicine, 2019, 13, 823-838.	1.0	14
186	Proteomic Profiling to Identify Blood Biomarkers Predictive of Response to Azithromycin in Children and Adolescents With Cystic Fibrosis. Chest, 2019, 156, 667-673.	0.4	12
187	Treating the Airway Consequences of Cystic Fibrosis Transmembrane Conductance Regulator Dysfunction. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 751-761.	0.8	0
188	Long-term macrolide antibiotics for the treatment of bronchiectasis in adults: an individual participant data meta-analysis. Lancet Respiratory Medicine,the, 2019, 7, 845-854.	5.2	104
189	Targeting airway inflammation in cystic fibrosis. Expert Review of Respiratory Medicine, 2019, 13, 1041-1055.	1.0	16
190	A Multidisciplinary Approach to Pretransplant and Posttransplant Management of Cystic Fibrosisâ€“Associated Liver Disease. Liver Transplantation, 2019, 25, 640-657.	1.3	19
191	Pulmonary exacerbations in patients with primary ciliary dyskinesia: an expert consensus definition for use in clinical trials. ERJ Open Research, 2019, 5, 00147-2018.	1.1	37

#	Article	IF	Citations
192	Chronic antibiotic use during adulthood and weight change in the Sister Study. PLoS ONE, 2019, 14, e0216959.	1.1	9
193	Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis. BMC Medical Research Methodology, 2019, 19, 88.	1.4	8
194	Double-blind, placebo-controlled, randomized trial on low-dose azithromycin prophylaxis in patients with primary antibody deficiencies. Journal of Allergy and Clinical Immunology, 2019, 144, 584-593.e7.	1.5	54
195	Long-Term Azithromycin Reduces Haemophilus influenzae and Increases Antibiotic Resistance in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 309-317.	2.5	121
196	Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial. American Journal of Clinical Nutrition, 2019, 109, 544-553.	2.2	27
197	Adverse events in people taking macrolide antibiotics versus placebo for any indication. The Cochrane Library, 2019, 2019, CD011825.	1.5	55
198	Prevention of chronic infection with Pseudomonas aeruginosa infection in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2019, 25, 636-645.	1.2	5
199	Prevention of drug-related complications in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2019, 25, 666-673.	1.2	2
200	A review of nonâ€cystic fibrosis bronchiectasis in children with a focus on the role of longâ€term treatment with macrolides. Pediatric Pulmonology, 2019, 54, 487-496.	1.0	11
201	Depletion of BAFF cytokine exacerbates infection in Pseudomonas aeruginosa infected mice. Journal of Cystic Fibrosis, 2019, 18, 349-356.	0.3	6
202	Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohnâ€™s disease : a randomised controlled trial. Gut, 2019, 68, 239-247.	6.1	27
203	Blood biomarkers to predict short-term pulmonary exacerbation risk in children and adolescents with CF: A pilot study. Journal of Cystic Fibrosis, 2020, 19, 49-51.	0.3	9
204	Azithromycin is the answer in paediatric respiratory medicine, but what was the question?. Paediatric Respiratory Reviews, 2020, 34, 67-74.	1.2	16
205	Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 430-437.	2.5	50
206	Quantifying Long-Term Changes in Lung Function and Exacerbations after Initiation of Azithromycin in Cystic Fibrosis. Annals of the American Thoracic Society, 2020, 17, 195-201.	1.5	7
207	Evaluating Long-Term Benefits of Chronic Azithromycin. Furthering Our Quest for Precision Medicine. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 398-400.	2.5	7
209	Will Airway Gene Therapy for Cystic Fibrosis Improve Lung Function? New Imaging Technologies Can Help Us Find Out. Human Gene Therapy, 2020, 31, 973-984.	1.4	5
210	Accelerated Approval or Risk Reduction? How Response Biomarkers Advance Therapeutics through Clinical Trials in Cystic Fibrosis. Trends in Molecular Medicine, 2020, 26, 1068-1077.	3.5	7

#	Article	IF	Citations
211	Novel Anti-Inflammatory Approaches for Cystic Fibrosis Lung Disease: Identification of Molecular Targets and Design of Innovative Therapies. Frontiers in Pharmacology, 2020, 11, 1096.	1.6	30
212	Motile ciliopathies. Nature Reviews Disease Primers, 2020, 6, 77.	18.1	191
213	Comparative evaluation of the effect of different growth media on in vitro sensitivity to azithromycin in multi-drug resistant Pseudomonas aeruginosa isolated from cystic fibrosis patients. Antimicrobial Resistance and Infection Control, 2020, 9, 197.	1.5	9
214	Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 493-505.	5.2	79
215	Mycobacterium abscessus Clearance by Neutrophils Is Independent of Autophagy. Infection and Immunity, 2020, 88, .	1.0	13
216	Gram negative infections in cystic fibrosis: a review of preventative and treatment options. Expert Opinion on Orphan Drugs, 2020, 8, 11-26.	0.5	2
217	Cystic fibrosis 2019: Year in review. Paediatric Respiratory Reviews, 2020, 35, 95-98.	1.2	4
218	Myeloid arginase-1 controls excessive inflammation and modulates T cell responses in Pseudomonas aeruginosa pneumonia. Immunobiology, 2021, 226, 152034.	0.8	3
219	Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment. Annals of the American Thoracic Society, 2021, 18, 266-272.	1.5	8
220	Novel Immunomodulatory Therapies for Respiratory Pathologies. , 2022, , 554-594.		5
221	A Review of The Role of The Microbiome on Immune Responses and Its Association With Cystic Fibrosis. Immunoregulation, 2021, 3, 75-88.	0.1	0
222	Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. Frontiers in Immunology, 2021, 12, 574425.	2.2	38
223	Azithromycin and the microbiota of cystic fibrosis sputum. BMC Microbiology, 2021, 21, 96.	1.3	14
224	Rates of adverse and serious adverse events in children with cystic fibrosis. Journal of Cystic Fibrosis, 2021, 20, 972-977.	0.3	3
225	Treatment of Pulmonary Disease of Cystic Fibrosis: A Comprehensive Review. Antibiotics, 2021, 10, 486.	1.5	15
226	Do Antibiotics Cause Obesity Through Long-term Alterations in the Gut Microbiome? A Review of Current Evidence. Current Obesity Reports, 2021, 10, 244-262.	3.5	47
227	Cystic fibrosis. Lancet, The, 2021, 397, 2195-2211.	6.3	316
228	Microbial Cystic Fibrosis. , 0, , .		0

#	Article	IF	Citations
229	Long-term, low-dose macrolide antibiotic treatment in pediatric chronic airway diseases. Pediatric Research, 2022, 91, 1036-1042.	1.1	13
230	Impact of chest computed tomography scan on the management of patients with chronic cough. ERJ Open Research, 2021, 7, 00222-2021.	1.1	6
231	Study protocol for a randomised controlled trial evaluating the clinical effect of antibiotic prophylaxis in children with recurrent respiratory tract infections: the Approach study. BMJ Open, 2021, 11, e044505.	0.8	0
232	Pregnancy in cystic fibrosis: Review of the literature and expert recommendations. Journal of Cystic Fibrosis, 2022, 21, 387-395.	0.3	28
233	The Gut-Lung Axis in Cystic Fibrosis. Journal of Bacteriology, 2021, 203, e0031121.	1.0	44
234	Retracing changes in cystic fibrosis understanding and management over the past twenty years. Journal of Cystic Fibrosis, 2022, 21, 3-9.	0.3	3
235	Cystic Fibrosis Therapies. , 2022, , 179-187.		0
236	Effect of Once-Weekly Azithromycin vs Placebo in Children With HIV-Associated Chronic Lung Disease. JAMA Network Open, 2020, 3, e2028484.	2.8	23
237	Macrolides, Azalides, and Ketolides. , 2011, , 243-275.		1
238	Antibiotic susceptibility and molecular mechanisms of macrolide resistance in streptococci isolated from adult cystic fibrosis patients. Journal of Medical Microbiology, 2015, 64, 1375-1386.	0.7	14
241	Management of primary ciliary dyskinesia: current practice and future perspectives. , 0, , 282-299.		6
242	Targeting the Pseudomonas aeruginosa biofilm to combat infections in patients with cystic fibrosis. Drugs of the Future, 2010, 35, 1007.	0.0	13
243	Pulmonary Exacerbations in Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2015, 12, S200-S206.	1.5	62
244	Which patients with respiratory disease need long-term azithromycin?. Cleveland Clinic Journal of Medicine, 2017, 84, 755-758.	0.6	3
245	Nebulized Azithromycin Versus Oral Azithromycin as Anti-Inflammatory Therapy in Children with Cystic Fibrosis: A Prospective Randomized Open-Label Trial. Iranian Journal of Pediatrics, 2019, In Press, .	0.1	3
246	Safety of azithromycin in pediatric infectious diseases: a clinical systematic review and meta-analysis. Translational Pediatrics, 2021, 10, 2594-2601.	0.5	3
247	Heterogeneity of treatment response in bronchiectasis clinical trials. European Respiratory Journal, 2022, 59, 2100777.	3.1	21
249	Pulmonary Inflammation in Cystic Fibrosis: Impact of Innate Immunity and Estrogen. International Journal of Clinical Reviews, 0, , .	0.1	0

#	Article	IF	Citations
250	Macrolides, Reflux and Respiratory Disease. , 2018, , 303-331.		0
251	Clinical Application of Stem/Stromal Cells in Cystic Fibrosis. , 2019, , 179-198.		0
252	Nonantimicrobial Actions of Macrolides: Overview and Perspectives for Future Development. Pharmacological Reviews, 2021, 73, 1404-1433.	7.1	40
253	Testing the effects of combining azithromycin with inhaled tobramycin forP. aeruginosain cystic fibrosis: a randomised, controlled clinical trial. Thorax, 2022, 77, 581-588.	2.7	12
254	Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages. European Respiratory Journal, 2021, 57, 2003502.	3.1	17
255	Maintenance of Pulmonary Therapies. Respiratory Medicine, 2020, , 199-213.	0.1	0
256	The immunomodulatory effects of macrolide antibiotics in respiratory disease. Pulmonary Pharmacology and Therapeutics, 2021, 71, 102095.	1.1	41
257	Long-term oral antibiotic treatment: why, what, when and to whom?. , 0, , 185-205.		0
258	Antibiotic management and resistance. , 0, , 312-330.		0
260	The Effect of Azithromycin on Structural Lung Disease in Infants with Cystic Fibrosis (COMBAT CF): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Clinical Trial. SSRN Electronic Journal, 0, , .	0.4	0
261	Is the safety of azithromycin superior to other antibiotics in the treatment of infectious diseases in children?. Translational Pediatrics, 2021, 11, 0-0.	0.5	0
262	Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas. Journal of Cystic Fibrosis, 2022, 21, 946-949.	0.3	5
263	Assessment of Long-Term Macrolide Exposure on the Oropharyngeal Microbiome and Macrolide Resistance in Healthy Adults and Consequences for Onward Transmission of Resistance. Antimicrobial Agents and Chemotherapy, 2022, 66, e0224621.	1.4	6
264	Delivering macrolide antibiotics to heal a broken heart â€“ And other inflammatory conditions. Advanced Drug Delivery Reviews, 2022, 184, 114252.	6.6	5
265	EVALUATING THE EFFICACY OF HUMAN BRONCHIECTASISBASED ANTIBIOTIC THERAPY IN THE TREATMENT OF ORANGUTAN RESPIRATORY DISEASE SYNDROME. Journal of Zoo and Wildlife Medicine, 2021, 52, 1205-1216.	0.3	1
271	The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): a phase 3, randomised, double-blind, placebo-controlled clinical trial. Lancet Respiratory Medicine,the, 2022, 10, 776-784.	5.2	14
272	Optimization and Characterization of a Liposomal Azithromycin Formulation for Alternative Macrophage Activation. Frontiers in Drug Delivery, 0, 2, .	0.4	0
274	Antibiotherapy in Children with Cystic Fibrosisâ€”An Extensive Review. Children, 2022, 9, 1258.	0.6	5

#	Article	IF	Citations
275	Is CF airway inflammation still relevant in the era of highly effective modulators?. Journal of Cystic Fibrosis, 2022, , .	0.3	0
276	Systemic Corticosteroids in the Management of Pediatric Cystic Fibrosis Pulmonary Exacerbations. Annals of the American Thoracic Society, 0, , .	1.5	0
277	Drugs, Drugs, Drugs: Current Treatment Paradigms in Cystic Fibrosis Airway Infections. Journal of the Pediatric Infectious Diseases Society, 2022, 11, S32-S39.	0.6	4
278	Antimicrobial Stewardship in Cystic Fibrosis. Journal of the Pediatric Infectious Diseases Society, 2022, 11, S53-S61.	0.6	3
279	Challenges and Considerations for Clinical Trials Design in Bronchiectasis. Respiratory Medicine, 2022, , 199-209.	0.1	0
280	Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis. Clinics in Chest Medicine, 2022, 43, 617-630.	0.8	2
281	Divergent dynamics of inflammatory mediators and multiplex PCRs during airway infection in cystic fibrosis patients and healthy controls: Serial upper airway sampling by nasal lavage. Frontiers in Immunology, 0, 13, .	2.2	3
282	Lessons from other fields of medicine, Part 2: Cystic fibrosis. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2023, , 119-130.	1.0	1
283	Outpatient management of pulmonary exacerbations in children with cystic fibrosis. Expert Review of Respiratory Medicine, 2023, 17, 295-304.	1.0	1
284	Orangutan Respiratory Disease Syndrome. , 2023, , 685-694.		0
290	Macrolides and Cystic Fibrosis. , 2024, , 59-92.		0